Connelly Robert 4
4 · Elicio Therapeutics, Inc. · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
Elicio (ELTX) CEO Robert Connelly Receives Stock Option Award
What Happened Robert Connelly, CEO, President and Director of Elicio Therapeutics (ELTX), received a derivative award covering 186,944 shares on July 16, 2026. The grant is reported at $0.00 per share (award/derivative), indicating an option/award rather than a cash purchase; no immediate cash value or exercise price is shown in the provided excerpt.
Key Details
- Transaction date: 2026-07-16; Form 4 filed 2026-07-17 (timely).
- Transaction type/code: A (Grant, award or other acquisition — derivative security).
- Quantity: 186,944 derivative securities (options/awards) acquired at $0.00 per share in the filing excerpt.
- Vesting: 50% vests and becomes exercisable on July 16, 2027; remaining 50% vests on July 16, 2028, subject to continued service (per footnote).
- Exercise price / total grant value: Not disclosed in the provided excerpt.
- Shares owned after transaction: Not specified in the provided excerpt.
- Filing status: Timely (no late filing indicated).
Context This was a compensation grant to the CEO (an award of derivative securities/options) rather than an open-market buy or sale. Such grants are commonly used to align executive incentives with shareholder value; they do not represent an immediate cash investment or sale. There is no indication from this filing that any shares were exercised or sold.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-07-16+186,944→ 186,944 totalExercise: $3.20Exp: 2036-07-16→ Common Stock (186,944 underlying)
Footnotes (1)
- [F1]The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.